Clinical efficacy and safety of icodextrin dialysate for overnight dwell in continuous ambulatory peritoneal dialysis: A prospective self-controlled study.

ObjectiveTo analyze the clinical benefits of icodextrin in patients undergoing continuous ambulatory peritoneal dialysis to optimize treatment strategies.MethodsThis prospective single-arm, self-controlled observational study enrolled 50 peritoneal dialysis patients. All eligible participants were consecutively enrolled according to uniform inclusion and exclusion criteria during the study period. Each patient sequentially received 6 months of treatment with a standard peritoneal dialysis solution, followed by 6 months of treatment with an icodextrin-based solution. Written informed consent was obtained from all participants before study enrollment.ResultsCompared with the standard glucose-based solution phase, the subsequent 6-month icodextrin-based regimen significantly improved key clinical parameters. Significant increases were observed in 24-h ultrafiltration volume, Kt/V, serum albumin levels, and hemoglobin levels, whereas C-reactive protein and B-type natriuretic peptide levels significantly decreased (p < 0.05). There was a significant difference in the distribution of 24-h urine volume (p < 0.0001), and no severe adverse events were reported.ConclusionOvernight use of icodextrin dialysate in patients undergoing continuous ambulatory peritoneal dialysis can effectively enhance ultrafiltration and dialysis adequacy and improve inflammation, fluid overload, anemia, and malnutrition, with satisfactory safety. Icodextrin is a reliable option for individualized peritoneal dialysis regimen optimization.